Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24


Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.

Mann K, Torup L, Sørensen P, Gual A, Swift R, Walker B, van den Brink W.

Eur Neuropsychopharmacol. 2016 Dec;26(12):1941-1949. doi: 10.1016/j.euroneuro.2016.10.008. Epub 2016 Nov 12. Review.


Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.

Aubin HJ, Reimer J, Nutt DJ, Bladström A, Torup L, François C, Chick J.

Eur Addict Res. 2015;21(3):160-8. doi: 10.1159/000371547. Epub 2015 Mar 31.


Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials.

Witkiewitz K, Falk DE, Kranzler HR, Litten RZ, Hallgren KA, O'Malley SS, Anton RF; Alcohol Clinical Trials Initiative (ACTIVE) Workgroup.

Alcohol Clin Exp Res. 2014 Nov;38(11):2826-34. doi: 10.1111/acer.12543.


What happens when people discontinue taking medications? Lessons from COMBINE.

Stout RL, Braciszewski JM, Subbaraman MS, Kranzler HR, O'Malley SS, Falk D; ACTIVE group.

Addiction. 2014 Dec;109(12):2044-52. doi: 10.1111/add.12700. Epub 2014 Sep 12.


Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.

van den Brink W, Sørensen P, Torup L, Mann K, Gual A; SENSE Study Group.

J Psychopharmacol. 2014 Aug;28(8):733-44. doi: 10.1177/0269881114527362. Epub 2014 Mar 26.


Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.

Falk DE, Litten RZ, Anton RF, Kranzler HR, Johnson BA; Active Workgroup.

J Stud Alcohol Drugs. 2014 Mar;75(2):335-46.


Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.

van den Brink W, Aubin HJ, Bladström A, Torup L, Gual A, Mann K.

Alcohol Alcohol. 2013 Sep-Oct;48(5):570-8. doi: 10.1093/alcalc/agt061. Epub 2013 Jul 19. Erratum in: Alcohol Alcohol. 2013 Nov-Dec;48(6):746.


A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42. doi: 10.1016/j.euroneuro.2013.02.006. Epub 2013 Apr 3.


Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

Mann K, Bladström A, Torup L, Gual A, van den Brink W.

Biol Psychiatry. 2013 Apr 15;73(8):706-13. doi: 10.1016/j.biopsych.2012.10.020. Epub 2012 Dec 11.


Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.

Sams AG, Mikkelsen GK, Larsen M, Langgård M, Howells ME, Schrøder TJ, Brennum LT, Torup L, Jørgensen EB, Bundgaard C, Kreilgård M, Bang-Andersen B.

J Med Chem. 2011 Feb 10;54(3):751-64. Epub 2011 Jan 6.


Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.

Sams AG, Mikkelsen GK, Larsen M, Torup L, Brennum LT, Schrøder TJ, Bang-Andersen B.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5241-4. doi: 10.1016/j.bmcl.2010.06.138. Epub 2010 Jul 24.


Update of the stroke therapy academic industry roundtable preclinical recommendations.

Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH; STAIR Group.

Stroke. 2009 Jun;40(6):2244-50. doi: 10.1161/STROKEAHA.108.541128. Epub 2009 Feb 26. Review.


High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).

Kirkeby A, Torup L, Bochsen L, Kjalke M, Abel K, Theilgaard-Monch K, Johansson PI, Bjørn SE, Gerwien J, Leist M.

Thromb Haemost. 2008 Apr;99(4):720-8. doi: 10.1160/TH07-03-0208.


The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells.

Wang L, Zhang ZG, Gregg SR, Zhang RL, Jiao Z, LeTourneau Y, Liu X, Feng Y, Gerwien J, Torup L, Leist M, Noguchi CT, Chen ZY, Chopp M.

J Biol Chem. 2007 Nov 2;282(44):32462-70. Epub 2007 Sep 5.


Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat.

King VR, Averill SA, Hewazy D, Priestley JV, Torup L, Michael-Titus AT.

Eur J Neurosci. 2007 Jul;26(1):90-100.


Neuroprotection with or without erythropoiesis; sometimes less is more.

Torup L.

Br J Pharmacol. 2007 Aug;151(8):1141-2. Epub 2007 May 29.


Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo.

Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L, Van Beek J, Leist M, Brines M, Cerami A, Ghezzi P.

Mol Med. 2006 Jul-Aug;12(7-8):153-60.


Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives.

Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L.

J Cereb Blood Flow Metab. 2007 Mar;27(3):552-63. Epub 2006 Jul 12.


Derivatives of erythropoietin that are tissue protective but not erythropoietic.

Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M.

Science. 2004 Jul 9;305(5681):239-42.


Supplemental Content

Loading ...
Support Center